Firmagon

Firmagon is the only gonadotrophin releasing hormone (GnRH) receptor antagonist indicated for the treatment of adult patients with advanced hormone-dependent prostate cancer in the UK.1

Firmagon’s mode of action is different from luteinising hormone releasing (LHRH) agonists allowing it to provide better overall disease control.2

Prescribing Information and Adverse Event Reporting

Prescribing information for you and your patient including dosing and potential side effects.

Alternatively the SmPC can be accessed via the EMC website:

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard.
Adverse events should also be reported to Ferring Pharmaceuticals Ltd.
Tel: 0800 111 4126, Email: mailto:medical.uk@ferring.com

How Firmagon works

Firmagon works by directly blocking pituitary GnRH receptors to supress follicle-stimulating hormone (FSH) and luteinising hormone (LH). This results in the rapid suppression of testosterone to castrate levels which is achieved within 1-3 days.6

Firmagon does not cause a testosterone surge on initiation or on subsequent maintenance injections eliminating the need for anti-androgens.1,3-6 Additionally, patients do not experience any exacerbated clinical symptoms from a flare caused by testosterone surges.1,3

Firmagon provides a significantly improved and effective PSA progression free survival 2-6, better serum alkaline phosphatase (S-ALP) control and potentially longer control of skeletal metastases compared to LHRH agonists.3,5 In addition, there is a lower probability of CV events with Firmagon than with agonists in patients with pre-existing cardiovascular disease.7,8

Firmagon

(degarelix)

Product Information

Product Information

Firmagon works by directly blocking pituitary GnRH receptors to supress follicle-stimulating hormone (FSH) and luteinising hormone (LH). This results in the rapid suppression of testosterone to castrate levels which is achieved within 1-3 days.6

Firmagon does not cause a testosterone surge on initiation or on subsequent maintenance injections eliminating the need for anti-androgens.1,3-6 Additionally, patients do not experience any exacerbated clinical symptoms from a flare caused by testosterone surges.1,3

Firmagon provides a significantly improved and effective PSA progression free survival,2-6 better serum alkaline phosphatase (S-ALP) control and potentially longer control of skeletal metastases compared to LHRH agonists.3,5 In addition, there is a lower probability of CV events with Firmagon than with agonists in patients with pre-existing cardiovascular disease.7,8

Firmagon Patient Video

Watch our video clip featuring patients on Firmagon describing their experience and journey from diagnosis to where they are today.

Dosing and Administration Video

Firmagon is a subcutaneous injection administered to the abdominal region. It should be administered at a slow and steady pace over 30 seconds.

Injection sites should be varied and not be in areas where the patient will be exposed to pressure e.g. not close to waistband/ belt. Treatment should be continued after initiation and it should only be administered by a healthcare professional.

The injection site should be kept clean and patients should avoid rubbing the area. If your patient experiences a reaction at the injection site, it can be managed with paracetamol or ibuprofen or cooling methods e.g. ice packs.
Please watch this video for more information and guidance.

Are you a Health Care Professional?

The following information is intended for UK Healthcare Professionals (HCPs). It contains information about prescribing, plus relevant patient information.

UY/2407/2017/UK September 2017